Search results
Results From The WOW.Com Content Network
Rs. 21.05 billion (US$73 million) [ 1] (2022) Number of employees. 1,768 [ 1] (2022) Parent. GSK. Website. www .pk .gsk .com. GlaxoSmithKline Pakistan is a Pakistani pharmaceutical company which is a subsidiary of British company GSK. [ 2] It is the largest pharmaceutical company in Pakistan.
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with global headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
Rotarix (human rotavirus vaccine, live attenuated) Shingrix (for Zoster Vaccine Recombinant, Adjuvanted) Synflorix (pneumococcal polysaccharide conjugate vaccine (adsorbed)) Twinrix (for combined hepatitis A (inactivated virus) and hepatitis B vaccine (genetically derived surface antigen)) Typherix (typhoid vaccine (purified polysaccharide ...
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [ 4][ 5] The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology ...
The pharmaceutical industry in Pakistan was estimated to be worth Rs. 748 billion (US$2.6 billion) in 2023, representing about 1% of the country's GDP. [ 1] The industry is largely import-dependent, with more than 90% of raw material being imported and only 12% of APIs locally produced. [ 1] Pakistani pharmaceutical companies are engaged in ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Haleon was established on 18 July 2022 as a corporate spin-off from GSK. [6] Sir David Lewis is chairman, with Brian McNamara as CEO. [7] Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in ...
The article Anacor Pharmaceuticals Announces That GSK Has Discontinued Clinical Development of GSK2251052 originally appeared on Fool.com. Try any of our Foolish newsletter services free for 30 days .